Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR)
Authors' conclusion
C-peptide mQR was feasible and produced expected responder frequencies following low-dose ATG in a clinical practice setting.
Study context
- Population
- Individuals with stage 2 or stage 3 T1D treated clinically with low-dose antithymocyte globulin (ATG)22 evaluable · Individuals with stage 2 6 · or stage 3 33
- Outcome
- Modified quantitative response (mQR) of C-peptide, from AUC C-peptide estimated from 90-min values after 6 mL/kg Boost
- Follow-up
- 1 year
Methodological detailsexploratory, single-group, clinical practice setting
- Exploratory
- Single-group
- Clinical practice setting
Main finding
As reported in the abstract
C-peptide mQR at 1 year
Average mQR at 1 year in evaluable patients
0.072
Responders (+mQR)
15
Nonresponders (-mQR)
7
Observational data: associations, not effects.
Further findings
HbA1c, pre-ATG to 1 year
- Average HbA1c before ATG
- 7.1% (54 mmol/mol)
- Average HbA1c at follow-up
- 6.0% (42 mmol/mol)
Follow-up completion · 1 year
- Completed 1 year of follow-up
- 30 (77%)
- Provided pre-ATG and 1-year C-peptides
- 22 (73% of those)
Safety
- There were no unexpected side effects
Original publication
Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR). Diabetes Care. Published 5 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →